Berenson, James R <br/><br/>
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Mar 2007 
 - 1762-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-06-1812  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Arsenic Trioxide<br/>Arsenicals--administration & dosage<br/>Ascorbic Acid--administration & dosage<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Oxides--administration & dosage<br/>Pyrazines--administration & dosage<br/>Recurrence<br/>Survival Analysis<br/>Treatment Failure<br/>Treatment Outcome